AI drug announcement could change biotech forever
TOMORROW: AI to save 3 million lives?  | | JAMES
ALTUCHER | Dear Reader, We are about to have the answer to a question that could inevitably help save 3 million lives. “Can AI solve a deadly, incurable disease?” One tiny company has spent months using AI to develop a drug in record time… And TOMORROW, on August 23, they’ll announce their results to the world. This will be the first domino of a huge trend sweeping the pharmaceutical industry - Using AI to develop unique, never-before-seen medicines to cure deadly diseases. This catalyst - occurring at the intersection of AI and biotech, two of the market’s biggest sectors - could immediately trigger a mass market rally. One that I want YOU to get in on. That’s why I’ve put this video together for you. You have 24 hours to view it. This tiny AI company could make their market-altering announcement any time after tomorrow’s opening bell… And you need to be in position before that. Get all the details right here. Sincerely, | | | | | |
| | © 2024 Paradigm Press, LLC. 1001 Cathedral Street, Baltimore, MD 21201. By submitting your email address, you consent to Paradigm Press, LLC. delivering daily email issues and advertisements. To end your Altucher's A-List e-mail subscription and associated external offers sent from Altucher's A-List, feel free to click here. Please note: the mailbox associated with this email address is not monitored, so do not reply to this message. We welcome comments or suggestions at feedback@paradigmpressgroup.com. This address is for feedback only. For questions about your account or to speak with customer service, contact us here or call (844)-731-0984. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of a printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Altucher's A-List is committed to protecting and respecting your privacy. We do not rent or share your email address. Please read our Privacy Statement. If you are having trouble receiving your Altucher's A-List subscription, you can ensure its arrival in your mailbox by whitelisting Altucher's A-List. | | |
No comments:
Post a Comment
Keep a civil tongue.